John H. Powers

10.9k total citations · 3 hit papers
136 papers, 5.7k citations indexed

About

John H. Powers is a scholar working on Epidemiology, Infectious Diseases and Economics and Econometrics. According to data from OpenAlex, John H. Powers has authored 136 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Epidemiology, 31 papers in Infectious Diseases and 27 papers in Economics and Econometrics. Recurrent topics in John H. Powers's work include Antibiotic Use and Resistance (26 papers), Health Systems, Economic Evaluations, Quality of Life (21 papers) and Antibiotic Resistance in Bacteria (17 papers). John H. Powers is often cited by papers focused on Antibiotic Use and Resistance (26 papers), Health Systems, Economic Evaluations, Quality of Life (21 papers) and Antibiotic Resistance in Bacteria (17 papers). John H. Powers collaborates with scholars based in United States, United Kingdom and Mexico. John H. Powers's co-authors include Thomas R. Fleming, Tom Chiller, Eric P. Brass, Loren G. Miller, John E. Edwards, Brad Spellberg, Donald L. Patrick, Laurie B. Burke, Frederick J. Angulo and Jennifer Nelson and has published in prestigious journals such as New England Journal of Medicine, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

John H. Powers

128 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trends in Antimicrobial Drug Development: Implications for the Future

2004 633 citations John H. Powers et al. Clinical Infectious Diseases profile →
Patient-Reported Outcomes to Support Medical Product Labeling Claims: FDA Perspective

2007 555 citations John H. Powers et al. Value in Health profile →
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents

2018 377 citations Sameer S. Kadri, John H. Powers et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John H. Powers United States	33	1.3k	1.1k	943	922	675	136	5.7k
Daniel J. Morgan United States	37	762 0.6×	662 0.6×	1.1k 1.2×	795 0.9×	637 0.9×	138	4.5k
Jon P. Furuno United States	37	1.2k 0.9×	853 0.8×	1.6k 1.7×	965 1.0×	368 0.5×	119	4.8k
Evelina Tacconelli Italy	37	1.7k 1.3×	1.6k 1.5×	2.4k 2.5×	1.7k 1.8×	902 1.3×	137	9.1k
Li Yang Hsu Singapore	46	1.5k 1.2×	2.0k 1.8×	2.6k 2.8×	1.1k 1.2×	647 1.0×	199	8.2k
Jessina C. McGregor United States	33	1.1k 0.9×	694 0.6×	999 1.1×	1.0k 1.1×	386 0.6×	115	4.1k
Dafna Yahav Israel	41	1.8k 1.4×	1.3k 1.2×	1.6k 1.7×	645 0.7×	1.1k 1.6×	207	5.5k
Hanan H. Balkhy Saudi Arabia	43	1.7k 1.3×	1.3k 1.2×	3.6k 3.8×	863 0.9×	313 0.5×	154	8.0k
Hung-Jen Tang Taiwan	29	805 0.6×	695 0.6×	2.4k 2.5×	278 0.3×	319 0.5×	68	5.9k
Katie J. Suda United States	33	1.9k 1.5×	361 0.3×	1.6k 1.7×	1.7k 1.8×	459 0.7×	249	5.5k
Cliodna McNulty United Kingdom	40	1.5k 1.2×	602 0.5×	783 0.8×	2.0k 2.2×	348 0.5×	211	5.7k

Countries citing papers authored by John H. Powers

Since Specialization

Citations

This map shows the geographic impact of John H. Powers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John H. Powers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John H. Powers more than expected).

Fields of papers citing papers by John H. Powers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John H. Powers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John H. Powers. The network helps show where John H. Powers may publish in the future.

Co-authorship network of co-authors of John H. Powers

This figure shows the co-authorship network connecting the top 25 collaborators of John H. Powers. A scholar is included among the top collaborators of John H. Powers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John H. Powers. John H. Powers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Powers, John H., Sameer S. Kadri, Sarah Warner, et al.. (2025). Demographics, epidemiology, mortality and difficult-to-treat resistance patterns of bacterial bloodstream infections in the global US Military Health System from 2010 to 2019: a retrospective cohort study. BMJ Open. 15(3). e094861–e094861.

Kesselheim, Aaron S., et al.. (2024). National Survey of Factors Associated with Physician Antibiotic Prescribing Preferences. Journal of General Internal Medicine. 40(4). 838–846.

Galindo‐Fraga, Arturo, Ana A. Ortiz‐Hernández, Ana M. Ortega‐Villa, et al.. (2024). Prospective cohort study of patient demographics, viral agents, seasonality, and outcomes of influenza-like illness in Mexico in the late H1N1-pandemic and post-pandemic years (2010-2014). IJID Regions. 12. 100394–100394.

Lawandi, Alexander, Sameer S. Kadri, & John H. Powers. (2023). Focusing on antimicrobial resistant infections –are we missing the forest for the trees and the patients for pathogens?. SHILAP Revista de lepidopterología. 2. 1329081–1329081. 1 indexed citations

Ortega‐Villa, Ana M., Ana A. Ortiz‐Hernández, Alejandra Ramírez‐Venegas, et al.. (2023). Etiology, clinical characteristics, and risk factors associated with severe influenza-like illnesses in Mexican adults. IJID Regions. 6. 152–158. 2 indexed citations

Curran, Desmond, et al.. (2022). Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross‐sectional study. Influenza and Other Respiratory Viruses. 16(3). 462–473. 15 indexed citations

Belaunzarán-Zamudio, Pablo F., Allyson Mateja, Héctor Armando Rincón-León, et al.. (2021). Comparison of clinical characteristics of Zika and dengue symptomatic infections and other acute illnesses of unidentified origin in Mexico. PLoS neglected tropical diseases. 15(2). e0009133–e0009133. 7 indexed citations

Powers, John H., et al.. (2020). Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999–2018. Mayo Clinic Proceedings. 95(12). 2699–2703. 3 indexed citations

Evans, Scott, Daniel B. Rubin, John H. Powers, & Dean Follmann. (2018). Analysis Populations in Anti-Infective Clinical Trials: Whom to Analyze?. PubMed. 10(1). 4 indexed citations

10.

Talbot, George H., Anita Das, Stephanie S. Cush, et al.. (2018). Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. The Journal of Infectious Diseases. 219(10). 1536–1544. 53 indexed citations

11.

Evans, Scott & John H. Powers. (2017). Evaluating Anti-infective Drugs in the Resistant Pathogen Setting: Can We Use External Controls?. PubMed. 9(1). 1 indexed citations

12.

Outterson, Kevin, John H. Powers, Gregory W. Daniel, & Mark McClellan. (2015). Repairing the Broken Market for Antibiotic Innovation. SSRN Electronic Journal. 2 indexed citations

13.

Talbot, George H., et al.. (2015). Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health: Table 1.. Clinical Infectious Diseases. 62(5). 603–607. 27 indexed citations

14.

Howard, Kellee, et al.. (2014). Development Of A New Patient Reported Outcome (PRO) Measure For Community-Acquired Bacterial Pneumonia (CABP). Value in Health. 17(3). A280–A280. 2 indexed citations

15.

Leidy, Nancy Kline, Teresa K. Wilcox, Paul Jones, et al.. (2010). Standardizing Measurement of Chronic Obstructive Pulmonary Disease Exacerbations: Reliability and Validity of a Patient-reported Diary. American Journal of Respiratory and Critical Care Medicine. 183(3). 323–329. 138 indexed citations

16.

Collignon, Peter, John H. Powers, Tom Chiller, Awa Aïdara‐Kane, & Frank M. Aarestrup. (2009). World Health Organization Ranking of Antimicrobials According to Their Importance in Human Medicine: A Critical Step for Developing Risk Management Strategies for the Use of Antimicrobials in Food Production Animals. Clinical Infectious Diseases. 49(1). 132–141. 283 indexed citations

17.

Powers, John H.. (2007). Diagnosis and Treatment of Acute Otitis Media: Evaluating the Evidence. Infectious Disease Clinics of North America. 21(2). 409–426. 7 indexed citations

18.

Kluver, Randolph & John H. Powers. (1999). Civic discourse, civil society, and Chinese communities. 38 indexed citations

19.

Brown, Wendy J., et al.. (1998). Is life a party for young women. Queensland's institutional digital repository (The University of Queensland). 45(3). 21–26. 19 indexed citations

20.

Powers, John H.. (1995). On the intellectual structure of the human communication discipline. Communication Education. 44(3). 191–222. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact